ImmunityBio Enhances Advertising Compliance Following FDA Correspondence

Original: ImmunityBio Addresses FDA Correspondence and Reaffirms Commitment to Advertising Compliance

Businesswire•Apr 6, 20267 min

In a Nutshell

ImmunityBio, a biotechnology company based in Culver City, California, has responded to the U.S. Food and Drug Administration (FDA) regarding concerns about promotional materials. The company has removed a podcast from its website and confirmed that a cited television advertisement was never aired. It is implementing enhanced compliance measures to ensure adherence to FDA regulations.

Key Points

01ImmunityBio has addressed FDA concerns regarding promotional materials.
02The company removed a podcast and confirmed a television ad was never aired.
03Enhanced compliance measures include executive training and external oversight.
04The company aims to ensure accurate and balanced communications about its therapies.
05ImmunityBio's product, ANKTIVA®, is designed for treating non-muscle invasive bladder cancer.

In-Article Ad

Full Summary

ImmunityBio, Inc. (NASDAQ: IBRX), a biotechnology company based in Culver City, California, has taken significant steps to address concerns raised by the U.S. Food and Drug Administration (FDA) regarding its promotional practices. The company submitted a comprehensive response to the FDA's Office of Prescription Drug Promotion (OPDP) following issues identified on March 13, 2026, related to a podcast and a television advertisement. ImmunityBio confirmed that the television advertisement was never broadcast and has removed the identified podcast from its corporate website, also requesting its removal from third-party platforms. Richard Adcock, President and CEO of ImmunityBio, emphasized the company's commitment to promotional compliance and the distinction between investigational aspirations and approved therapies. The company is implementing corrective actions, including mandatory executive training and expanded promotional review protocols, to enhance compliance. ImmunityBio's product, ANKTIVA® (nogapendekin alfa inbakicept-pmln), is an interleukin-15 receptor agonist indicated for treating adult patients with BCG-unresponsive non-muscle invasive bladder cancer. The company aims to ensure that all promotional communications are accurate and comply with FDA regulations.

Key Figures

March 13, 2026

Date of FDA correspondence

Culver City, California

Location of ImmunityBio's headquarters

In-Article Ad

Why It Matters

These compliance measures aim to enhance the integrity of ImmunityBio's promotional practices, which could influence patient trust and market perceptions.

Who is affected

patients, healthcare providers, and investors

What to know

Patients and healthcare providers should stay informed about the compliance status and promotional materials related to ImmunityBio's products.

FAQ

ImmunityBio has removed the identified podcast from its website, confirmed that a television advertisement was never aired, and is implementing enhanced compliance measures.

ANKTIVA® is an interleukin-15 receptor agonist indicated for the treatment of adult patients with BCG-unresponsive non-muscle invasive bladder cancer.

✦